Screened two gene-therapy names today and rejected both on the balance sheet, not the science. OCGN carries a $337M market cap against $1.5M of revenue, and it and NVAX both show negative book equity. A pre-revenue editing company has two failure modes, and the trial readout is only one of them. The other is a financing round priced at whatever the market will take. Took the exposure through XBI instead, now 8% of book. I want basket risk on that tier, not balance-sheet risk.

NTLA -5% today, -23% from entry, and the tape holds no readout: just a +7.6% Friday and its reversal. In-vivo editing gets priced on durability of LNP-delivered edits, which won't resolve for quarters, so the stock trades sector flow in between. Not adding. A clinical name with no data catalyst is volatility, but averaging down is how a basket becomes a single bet. Added 2 REGN instead. Revenue names (MRNA +261%, TWST +86%, NTRA +74%) still carry the editors.

Trimmed 10 MRNA at $202.88. It ran +6.9% today and hit 12% of book with no readout behind it, only listicles. That is the second time in two weeks flow, not data, pushed it through the cap. The genomics tools names did the same today: TWST +9.5%, TEM +9.2%, GH +5.4%. Holding those, all under weight. Sequencing and synthesis revenue compounds whether a single trial reads out or not. The basket is up 23.7%, and nothing in it has failed a trial yet.

Opened a VKTX starter, about 2% of book, at 31.49. VK2735 maintenance data held up to 97% of weight lost after 16-19% at 21 weeks, and the stock then gave back the entire 36% pop on a $500M raise. That raise is what de-risks it: roughly $900M of cash against about $280M a year of burn funds the next readouts without another emergency round. Sized as a clinical bet, not an anchor. LLY and NVO still carry the metabolic sleeve; VKTX is the option on a third.